Navigation Links
Lung cancer survival rates improved through use of individualized chemotherapy
Date:8/31/2010

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology (JTO), analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) based on the histoculture drug response assay (HDRA). After seven years of study, researchers concluded that the use of adjuvant (post-operative) chemotherapy based on results of the in vitro HDRA improved the survival and prognosis of patients with NSCLC who had undergone surgery and whose results of the HDRA assay showed chemosensitivity to the specific drugs used for treatment.

The patients' chemosensitivity to cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine and irinotecan were examined by the HDRA assay. The patients in the study were then split into two groups: (1) those whose tumors were sensitive to at least two of the HDRA drugs and received two HDRA positive drugs per chemotherapy session (31 patients) and (2) those whose tumors were sensitive to one or none of the HDRA drugs and were treated with a combination of one HDRA positive drug and one HDRA negative or two HDRA negative drugs per chemotherapy session (34 patients).

The overall five-year survival rate for the prediction sensitive group given two HDRA positive drugs was 82.4 percent. In contrast, the five-year survival rate for the patients whose tumors indicated a low sensitivity or no sensitivity to the HDRA drugs and received one HDRA positive drug and one HDRA negative or two HDRA negative drugs was 40.1 percent. Additionally, the rate of relapse was lower for the patients in the prediction sensitive group. Relapse occurred in 29 percent of patients who were given two HDRA positive drugs per chemotherapy session while it occurred in 55.8 percent of patients who underwent the other treatment.

"Our research concluded that the HDRA assay seems to be useful for the selection of anticancer drugs in chemotherapy," explained lead investigator, Masayuki Tanahashi, MD. However, Dr. Tanahashi and his colleagues recommend further research into this treatment option.


'/>"/>

Contact: Colleen Butz
cbutz@spectrumscience.com
202-587-2557
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Tumor budding identified as predictor for unfavorable outcome in lung cancer
2. Preventive cancer surgeries save womens lives
3. Can Fruits, Veggies Help Ward Off Lung Cancer?
4. Increasing selenium intake may decrease bladder cancer risk
5. Diverse diet of veggies may decrease lung cancer risk
6. Moderate Drinking May Boost Risk of Breast Cancers Return
7. Use the common cold virus to target and disrupt cancer cells?
8. Double-therapy approach effectively inhibited brain cancer recurrence
9. New nuclear breast imaging technologies associated with higher cancer risks
10. Alcohol intake increases certain types of breast cancer
11. Nicotine binding to receptor linked to breast cancer cell growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... for veterinary professionals across the United States. The whole food nutrient solutions company ... patients and giving dog, cat and horse owners’ peace of mind. With the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... a talk highlighting the organization’s successful Care Transitions program at the ... talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of ...
(Date:5/5/2016)... ... ... In honor of National Nurses Week 2016, Aya Healthcare , the ... thank a nurse who's made a difference in their life. From Friday, May 6 ... of San Diego/Imperial Counties (up to $10,000) every time someone tells them via social ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Collection Bureau, Inc. ... Clark brings more than 15 years of experience within the healthcare revenue cycle industry. ... career as the Director of Patient Financial Services at Spectrum Health. While at Spectrum ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for iOS and Android devices. VisualDx is the first point of care ... support across general medicine. The system speeds diagnosis, therapy decisions and patient ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... Pa. , May 3, 2016 ACME ... Jack Whelan and Delaware County ... (naloxone HCI) Nasal Spray in all ACME ... U.S. Centers for Disease Control and Prevention (CDC), naloxone has saved ... when police officers in Delaware County were ...
Breaking Medicine Technology: